When was neoX Biotech founded?

neoX Biotech was founded in 2018 and raised its 1st funding round within a year of its incorporation.

Where is neoX Biotech located?

neoX Biotech is headquartered in Pudong, China.

Who is the current CEO of neoX Biotech?

Michael Chen of neoX Biotech. They have also founded 1 company.

How many employees does neoX Biotech have?

As of Jan 31, 2026, the latest employee count at neoX Biotech is 13.

Is neoX Biotech a funded company?

neoX Biotech is a funded company, having raised a total of $40M across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jun 01, 2018.

When was the latest funding round of neoX Biotech?

neoX Biotech's latest funding was a $***** Series A round on Jul 08, 2021, with participation from 4 investors.

Where does neoX Biotech rank among its competitors?

neoX Biotech ranks 19th amongst 131 active competitors, of which 39 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Atavistik, which secured $120M in Dec, 2025.

Who are the top competitors of neoX Biotech?

neoX Biotech's top competitors include Biognosys, Seer and BridGene Biosciences. Among them, Atavistik secured the most recent funding round in December, 2025.

neoX Biotech - 2026 Company Profile, Team, Funding & Competitors

neoX Biotech is a series A company based in Pudong (China), founded in 2018 by Michael Chen and Fan Liu. It operates as a Provider of research and characterization of protein-protein interactions to facilitate drug discovery. neoX Biotech has raised $40M in funding from investors like 5Y Capital, Sequoia Capital and Zhen Fund. The company has 131 active competitors, including 39 funded and 13 that have exited. Its top competitors include companies like Biognosys, Seer and BridGene Biosciences.

Company Details

Provider of research and characterization of protein-protein interactions to facilitate drug discovery. The company combines artificial intelligence, biophysics and high-throughput experimentation for the discovery of macromolecular and multi-specific drug modalities, through deep insights into dynamic protein-protein interactions.

Website: neoxbio.com
Email ID: *****@neoxbio.com

Key Metrics

Founded Year

2018

Location

Pudong, China

Stage

Series A

Total Funding

$40M in 4 rounds

Latest Funding Round

Series A, Jul 08, 2021, $*****

Investors

5Y Capital & 7 more

Ranked

19^th among 131 active competitors

Employee Count

13 as on Jan 31, 2026

Similar Companies

Innovaccer & 2447 more

View neoX Biotech's full profile

neoX Biotech has raised a total funding of $40M over 4 rounds. Its first funding round was on Jun 01, 2018. Its latest funding round was a Series A round on Jul 08, 2021 for $*****. 4 investors participated in its latest round. neoX Biotech has 8 institutional investors.

Here is the list of recent funding rounds of neoX Biotech:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 08, 2021	5740930	Series A	1527393	4458554	9883039	3942220
Feb 02, 2021	3926068	Series A	7529242	3666670	9894657	BAI Capital & 3 more
Jul 01, 2020	8246155	Seed	1660859	5321867	Sequoia Capital & 1 more	5Y Capital

Access funding benchmarks and valuations. Sign up today!

View details of neoX Biotech's funding rounds and investors

The founders of neoX Biotech are Michael Chen and Fan Liu. Michael Chen is the CEO of neoX Biotech.

Here are the details of neoX Biotech's key team members:

Michael Chen: Co-Founder & CEO of neoX Biotech and founder of 2 other companies, neoX and Belleds.
Contact Info: 1 email address
Fan Liu: Co-Founder of neoX Biotech.
Contact Info: 1 email address

View details of neoX Biotech's Founder profiles and Board Members

neoX Biotech's employee count trend

neoX Biotech has 13 employees as of Jan 26. Here is neoX Biotech's employee count trend over the years:

Uncover neoX Biotech's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of neoX Biotech include Biognosys, Seer and BridGene Biosciences. Here is the list of Top 10 competitors of neoX Biotech, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Biognosys 2008, Schlieren (Switzerland), Acquired	Provider of proteomics service	$9.13M	Zurcher Kantonalbank, Redalpine & 6 others	63/100
2nd	Seer 2017, San Francisco (United States), Public	Developer of proteomics platform for early detection of cancer and neurological diseases	$128M	aMoon, Invus & 15 others	61/100
3rd	BridGene Biosciences 2018, Sunnyvale (United States), Series B	Developer of small-molecule drugs for the treatment of cancer	$78.5M	Kaitai Capital Management, Deyi Capital & 7 others	60/100
4th	ProteinQure 2017, Toronto (Canada), Series A	Provider of computational protein drug design platform	$15M	Felicis Ventures, Government of Canada & 9 others	60/100
5th	Talus 2020, Seattle (United States), Seed	Provider of drug discovery platform for gene regulators	$19.8M	Fifty Years, Y Combinator & 10 others	59/100
6th	Unnatural Products 2016, Santa Cruz (United States), Series A	Developer of computational biology techniques platform to engineer peptides for undruggable targets	$38M	Artis Ventures, Merck Global Health Innovation Fund ... & 15 others	58/100
7th	Cyrus Biotechnology 2014, Seattle (United States), Series B	Developer of cloud-based protein-modelling software for drug discovery	$32M	Trinity Ventures, Orbimed & 11 others	57/100
8th	Peptone 2016, Amsterdam (Netherlands), Series A	Provider of an AI based protein analysis platform for research and development	$42.5M	F-Prime Capital, Bessemer Venture Partners ... & 6 others	57/100
9th	ProteinSimple 2004, San Jose (United States), Acquired	Provider tools to help researchers with protein analysis	$94.3M	Lansing Brown Investments, Royal Bank of Canada ... & 10 others	57/100
10th	Atavistik 2021, Cambridge (United States), Series B	Developer of allosteric therapeutics for precision oncology and rare diseases	$220M	The Column Group, Nextech Invest & 2 others	56/100
19th	neoX Biotech 2018, Pudong (China), Series A	Provider of research and characterization of protein-protein interactions to facilitate drug discovery	$40M	5Y Capital, Vertex Ventures & 6 others	46/100